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ABSTRACT
Introduction: Vascular-targeted drug delivery is a promising approach for the treatment of athero-
sclerosis, due to the vast involvement of endothelium in the initiation and growth of plaque, a
characteristic of atherosclerosis. One of the major challenges in carrier design for targeting cardiovas-
cular diseases (CVD) is that carriers must be able to navigate the circulation system and efficiently
marginate to the endothelium in order to interact with the target receptors.
Areas covered: This review draws on studies that have focused on the role of particle size, shape, and
density (along with flow hemodynamics and hemorheology) on the localization of the particles to
activated endothelial cell surfaces and vascular walls under different flow conditions, especially those
relevant to atherosclerosis.
Expert opinion: Generally, the size, shape, and density of a particle affect its adhesion to vascular walls
synergistically, and these three factors should be considered simultaneously when designing an optimal
carrier for targeting CVD. Available preliminary data should encourage more studies to be conducted to
investigate the use of nano-constructs, characterized by a sub-micrometer size, a non-spherical shape,
and a high material density to maximize vascular wall margination and minimize capillary entrapment,
as carriers for targeting CVD.
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1. Introduction
Despite significant clinical advances in the field, cardiovascular
diseases (CVDs) remain the leading cause of death and dis-
ability worldwide [1–3]. They account for 17.3 million deaths
per year, representing 30% of all global deaths, of which 80%
take place in low- and middle-income countries [1].
Atherosclerosis, a chronic inflammatory disease of the vascular
wall and a major cause of ischemic heart disease, is the most
common form of CVD and the leading cause of sudden death.
The process of atherosclerosis, which requires a complex inter-
play between various cells, particular monocytes, macro-
phages, and platelets [4,5], can ultimately lead to stroke,
heart attack, angina, heart failure, and peripheral vascular
disease. Once established, an atherosclerotic plaque can pro-
gress in two ways: the formation of either a stable plaque or
an unstable, vulnerable plaque [6]. Unstable, vulnerable ather-
osclerotic plaques are prone to rupture and consequently can
cause thrombosis, resulting in myocardial infarction and
stroke [7].
Numerous studies have been undertaken in attempts to
prevent, diagnose, and treat the often deadly complications
of atherosclerosis. Among these, nanomedicine as an emer-
ging field that utilizes nanotechnology concepts for advanced
therapy and diagnostics has attracted major interest. It has
been reported that the targeting of the plaques occurs via
both the vasa vasorum and the main lumen at the lesioned
sites [8,9]. Vasa vasorum is a network of small microvessels or
capillaries entering the plaques from the opposite site. Similar
to cancer, the key targeting principles in atherosclerosis can
be divided into nonspecific targeting through the enhanced
permeability and retention (EPR) effect and active targeting
toward vascular cells or specific components within the pla-
ques such as macrophages, lipoproteins, and cysteine pro-
teases. EPR mainly occurs through the permeability of the
microvascular systems or the leakiness of the neovessels of
the vasa vasorum. While the effect of the physical properties
of the nanomedicine on plaque targeting from the lumen site
has been studied widely, the effect of these properties on
plaque targeting via EPR in the vasa vasorum has been inves-
tigated limitedly. In this review, we focus on plaque targeting
from the lumen site.
In the last decades, vascular targeting has been explored
for localized delivery of therapeutics mainly in cancer [10,11],
but also increasingly in cardiovascular and pulmonary diseases
[12–14]. Vascular targeting plays a crucial role and is of parti-
cular interest for the diagnosis and treatment of atherosclero-
sis. This is because specific vascular wall endothelial cell
receptors associated with acute and chronic inflammation,
such as selectins, intercellular adhesion molecule 1 (ICAM-1),
and vascular cell adhesion molecule 1 (VCAM-1), play a major
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role in the pathology of this disease and can therefore serve as
local targeting epitopes [15].
One of the major challenges in carrier design for targeting
CVDs from the vessel lumen is that carriers must be able to
navigate the circulation system and efficiently marginate or
localize to the endothelium in order to interact with the target
receptors. Compared to nonspherical particles, spherical parti-
cles have been widely studied for targeting therapeutics to the
vascular wall due to their ease of fabrication and the existence
of well-defined models of hydrodynamic interactions [16–18].
Particles sized in the submicron down to tens of nanometers
range are particularly attractive for intravenous delivery, since
they can pass through the microcirculation with ease [17] and
are less susceptible to immune recognition and consequent
clearance [18,19]. However, in addition to the ability to navi-
gate the circulatory system, the particles should be designed
to drift laterally toward the vessel walls, like leukocytes during
an inflammatory process, rather than moving within the core
of the vessels, as red blood cells generally do in the macro-
and microcirculation [20]. The benefit of a highly specific
ligand–receptor targeting system is diminished if the particles
cannot interact with the target endothelium due to subopti-
mal deposition. Recently, particles with nonspherical shapes
[21,22] and micrometer sizes [15,23,24] have been increasingly
recognized as better carriers for targeting CVD. Particle density
has also appeared as an important factor affecting particle
margination to blood vessel walls [23,25].
Furthermore, vascular-targeted carriers must remain bound
long enough to release their drug cargo or to be internalized
by the endothelial cells [23]. The interaction between the
particle ligands and the cell surface receptors must be strong
to overcome the shear force and momentum on the particle
imparted by blood flow in order to result in firm adhesion. The
characteristic forces ascribed to blood flow dynamics (hemo-
dynamics) are a crucial element in the adhesive interactions of
vascular-targeted carriers with the endothelium, as hemody-
namics is known to be important for the binding of leukocytes
(white blood cells [WBCs]) with the endothelium – a hallmark
of the natural immune response. Therefore, hemodynamics
must be an important consideration in the design of vascu-
lar-targeted drug carriers. Here, we review the effects of phy-
sical characteristics of therapeutic carriers including size,
shape, and density, along with hemodynamics on the ability
of vascular-targeted drug/imaging carriers to marginate (loca-
lize and bind) to the vessel wall.
2. Blood flow in the presence of atherosclerosis
Blood is a complex aqueous fluid containing plasma (different
molecules and proteins) and cells including red blood cells
(RBCs), WBCs, and platelets [26]. Hemodynamics (particularly
blood shear rate and vessel size) and hemorheology (blood
rheology or blood hematocrit) are known to be important
factors in the interaction of WBCs with the endothelium in
vivo [26,27]. WBCs (8–12 μm diameter) are nearly twice as
large as RBCs, while platelets (1–3 μm diameter) are around
three times smaller than RBCs. Size and other physical proper-
ties of RBCs (shape and deformability) allow them to be pre-
ferentially confined within the core/center of the blood vessels
[28], forcing the other blood cells (WBCs and platelets) into an
almost RBC-free layer (RBC-FL) of plasma located toward the
vessel wall, thus promoting the interaction of WBCs and plate-
lets with the endothelium [29–32] .
The blood flow pattern changes during the development of
atherosclerosis [33]. Understanding blood flow is important for
the design and engineering of an optimally targeted vascular
nanoparticle for atherosclerosis. The extent of blood flow
within a vessel is directly proportional to pressure gradients
and inversely proportional to vascular resistance. Small
changes in vessel diameter due to a growing atherosclerotic
plaque can lead to substantial changes in vascular resistance,
thus changing the flow pattern significantly. Blood flow is
known to have a laminar pattern characterized by a parabolic
flow profile (Figure 1, left and right) [33,34]. When blood flow
transitions from a laminar, parabolic flow to a turbulent flow,
the blood flows across the vessel (no longer along it), and
vortices are formed which significantly increase the overall
flow resistance (Figure 1, middle). Turbulent/recirculating
flow, a direct function of blood velocity and inversely related
to viscosity, occurs when there are changes in the structure of
a vessel, such as an obstruction (Figure 1, middle), a sharp
turn, or a rough surface [35,36]. In laminar flow, the wall shear
stress is high while in disturbed flow it is lower. The areas of
the vasculature prone to developing atherosclerotic changes
tend to be large vessels and exhibit disturbed blood flow
profiles [37], including high pulsatility (regulated by the car-
diac cycle), low net shear due to reverse flow, and recirculation
eddies near areas of bifurcation or high curvature [38].
3. The role of particle size along with
hemodynamics and hemorheology
Atherosclerotic plaques preferentially develop at bifurcations of
blood vessels where disturbed flow and streamline separation
occur [24]. It has been shown that particle size and hemody-
namics affect the adhesion of particles to endothelium syner-
gistically. Generally, the binding of particles from blood flow to
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the inflamed endothelium generally increases with increasing
particle size, hematocrit, and wall shear rate (WSR).
3.1. Particle size
Charoenphol et al. found that the binding efficiency of poly-
meric spheres to the inflamed endothelium from laminar flow
of reconstituted blood (RBCs in homologous plasma with no
leukocyte or platelets) in vitro via parallel plate flow chamber
(PPFC) assays generally increased with increasing particle size
from 100 nm up to 10 μm [23]. These polymeric spheres were
functionalized with sialyl LewisA (sLeA), a carbohydrate ligand
specific to the endothelial-expressed selectins. In another
study, carboxylate-modified polystyrene spheres were functio-
nalized with sLeA, human ICAM-1 antibody (aICAM), or human
VCAM-1 antibody (aVCAM), which targeted molecules over-
expressed on the inflamed vascular wall [24]. Using in vitro
PPFC, these authors also found that the efficiency of particle
binding in disturbed and recirculating flows with reconstituted
blood increased as the spherical diameter increased from
500 nm to 5 μm. Disturbed flow includes pulsatile flow,
which is regulated by the cardiac cycle, and recirculation
flow, which occurs in areas with sudden flow expansion in
the arterial tree. Recirculation flow redistributes particle loca-
lization to the wall proximity, which increases the opportunity
for particle binding far downstream [24]. Nano-sized particles
showed minimal adhesion to the endothelium from blood
flow in horizontal (gravity and antigravity directions) and ver-
tical channels when compared to micron-sized spheres in all
flow types (laminar, disturbed/pulsed, and recirculating)
[23,24,27]. The channels used were on the order of small- to
medium-sized venules and arteries. This can be explained by
the poor ability of the nanoparticles from midstream to loca-
lize to the wall region [27] since they were strongly entrapped
within the RBC core that forms when blood flows [39]. No
significant difference was observed between the adhesion of
200 and 500 nm spheres [24]. In a mouse model of athero-
sclerosis, it was also found that 2 μm spheres displayed 2.5–3.5
times greater adhesion to the aortic wall than 500 nm spheres
[24]. This in vivo adhesion difference between nanospheres
and microspheres agrees well with observations from in vitro
assays using human blood [24].
These results are consistent with data fromNamdee et al. [15].
Using a mouse model of atherosclerosis, they demonstrated that
the adhesion of dual-targeted (E-selectin and VCAM-1) 2-μm
polystyrene particles to the inflamed aorta was greater than
that of their 500 nm counterparts (at least fourfold) [15]. The
adhesion was minimal for nanoparticles throughout the aorta
compared to microparticles, even in areas where very high levels
of inflammation were expected [15]. These results suggest that
micron-sized spherical particles (2 µm), rather than nanospheres,
are better for vascular-targeted drug delivery applications in
medium to large vessels relevant in atherosclerosis. Particles
with shapes other than spheres, such as disk-like and rod-like
particles, also exhibit the same behavior where a larger size
increases the binding efficiency [38,40]. For example, in PPFC
assays with reconstituted blood flow, rod-like particles with 2-μm
equivalent spherical diameters (ESDs) displayed higher margina-
tion than particles with either 1 μm or 500 nm ESDs [38]. In
another study, larger rods (1800 × 400 nm) were observed to
adhere at least three times more than smaller ones
(1500 × 200 nm) [40]. This can be explained by the higher drag
or higher settling velocity of larger particles compared to smaller
ones. Nanorods (500 nm ESD), even with high aspect ratios (ARs,
ratio between major axis and minor axis), did not display
enhanced margination compared to that of equivalent spheres
[38]. This indicates that, like nanospheres, nanorods display mini-
malmargination due to their inability to effectively localize to the
vessel wall in blood vessels or confined channels in vitro [38].
There are limited reports on the influence of the size of the disks
on their binding efficacy. Disks of intermediate size
(1000 × 400 nm) exhibited maximum adhesion compared with
disks of larger size (1800 × 600 nm) or smaller size
(600 × 200 nm), which reflects the balance between adhesive
interfacial interactions and hydrodynamic dislodging forces [40].
3.2. Size and hematocrit
It is widely known that RBCs play a crucial role in the margina-
tion of leukocytes and platelets. RBCs either promote or hinder
particle adhesion to endothelial cells in a PPFC depending on
the blood flow pattern, hematocrit, and particle size [41]. The
higher the hematocrit, the thinner the RBC-FL, resulting in
more frequent collisions between spheres and RBCs, and so
Figure 1. Baseline endothelial shear stress patterns along the course of a coronary artery obstruction.
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enhancing the lateral migration of spheres toward the walls
and promoting higher adhesion [41,42]. This explains the
increased binding at higher hematocrit observed for 0.5-μm
and 2-μm sLeA-coated polystyrene spheres in reconstituted
blood [41,42].
The same trend has been observed for both laminar flow
with WSR of 500 s−1 (the median of values measured in human
microvessels [43]) and pulsatile flow with peak WSR of
1000 s−1 (the typical pulsatile flow found in certain regions
of the large arteries relevant in atherosclerosis [37]) [41].
However, the higher hematocrit did not enhance the binding
of smaller (0.2 μm) or larger spheres (5.7 and 10 μm) [41]. In
recirculating flow (WSR = 200 s−1) via a vertical-step flow
channel (VSFC), there was no difference in the adhesion of
all spheres in the recirculation zone, while beyond flow reat-
tachment, only 2 μm and 5.7 μm spheres saw significant
increases in their binding levels with an increase in hematocrit,
which differs from what has been observed in other flow types
[41]. This is possibly due to the unique particle–RBC collision
dynamics known to exist in recirculating flow. The lack of a
hematocrit effect on the adhesion of 0.2 μm spheres across all
flow types may be due to their significantly larger RBC-FL-to-
particle-diameter ratio [41].
In a microcirculation setting with WSR of 200 s−1 (postca-
pillary venules [43,44]) and channel height of 254 μm (human
arterioles and venules [43,44]), the presence of RBCs also
enhanced the adhesion of sLeA-coated neutrally buoyant
spherical microparticles (≥2 μm diameter) to activated
endothelial cells from reconstituted blood flow [17,23]. The
binding efficiency for all particle sizes was further enhanced in
disturbed whole blood flow compared to reconstituted blood
flow [24]. This is likely due to the difference in hematocrit level
between the whole blood and the reconstituted blood of
∼45% and 30% hematocrit, respectively. Particles in the size
range of 100–500 nm are not preferentially distributed to the
vessel wall via the RBC effect, resulting in their low binding to
endothelium in the presence of physiological levels of RBCs
[23,26,27,38]. Small particles (≤100 nm) tend to circulate along
with RBCs and only a small fraction interacts with the vessel
walls [26], thus exhibiting minimal margination from bulk
blood flow [45,46].
3.3. Size and channel orientations
No significant difference was observed in adhesion levels
between adhesion in upward and downward flow for all par-
ticles tested in a vertical chamber [23]. The magnitudes of
particle binding in the horizontal channel and inverted hor-
izontal channel were almost the same [23]. This indicates that
there is a minimal contribution of gravity to particle localiza-
tion to the vessel wall. There was also no significance in the
magnitudes of particle adhesion to the wall observed between
vertical and horizontal chambers [23,24,47]. However, there
was a significant decrease in the adhesion observed for large
particles (5 and 10 μm) in the inverted versus the horizontal
chamber, which can be explained by potential differences in
the characteristics of the RBC-FL between the top and bottom
of the PPFC [23]. Reports in the literature have shown that the
average plasma layer thickness can differ significantly
between the top and bottom wall in a horizontally aligned
channel in vitro or a blood vessel in vivo [48,49].
3.4. Size and WSR
The adhesive behavior of the particles depends on the mag-
nitude of the WSR. In a PPFC system with laminar reconsti-
tuted blood flow at 200 s−1, the level of particle adhesion
increased with increasing particle size [23]. When the WSR
was increased to 500 s−1, the adhesion increased only when
the particle size also increased from 0.5 up to 5 μm. The
adhesion of 10 μm spheres at this WSR was significantly
lower than those measured for 2 and 5 μm particles. Further
increases in WSR to 1000 s−1 and 1500 s−1 resulted in adhesion
only increasing with a concomitant increase in particle size
from 0.5 to 2 μm. Particle sizes beyond 2 μm at these WSRs
resulted in the same or significantly lower level of binding
than displayed by 2-μm particles. It appears that for particles
≥2 μm, there is a critical WSR (WSRcrit) at which the binding
increases with increasing WSR up to WSRcrit, then drops with
WSR beyond the WSRcrit. This drop is due to the higher dis-
ruptive hemodynamic forces interfering with particle adhe-
sion, rather than ineffective particle localization to the wall
[23]. Overall, the magnitude of the WSRcrit decreased as the
particle size increases from 2 to 10 μm. Nanospheres do not
have a critical WSR: particles <2 μm display minimal adhesion
for all WSRs.
This coupling effect of size and WSR on the adhesion of
polymeric spheres has also been reported by Shinde
Patil et al. [50] and can be explained by (1) the transport of
particles to the vessel wall, typically regulated by convection
and diffusion; (2) the reaction between particle ligands and
cell surface receptors, controlled by receptor–ligand density
and particle slip velocity [51]; and (3) the detachment of
particles, regulated by WSR and the reverse reaction rate
[52]. Similarly, in a microfluidic model of human microvessels
employing 28 and 43 μm channels, the binding of nano-
spheres did not significantly change with increases in WSR
from 100 s–1 to 500 s–1 in both microchannels. However,
unlike what has been observed with the PPFC system, the
adhesion efficiency of microspheres in microchannels did not
increase with increasing WSR [27]. In particular, for 2-μm
polystyrene spheres, the adhesion efficiency slightly
decreased with an increase in WSR from 100 s–1 to 200 s–1
in the 43 μm channel, while it did not change with any
increases in WSR in the 28 μm channel. For 5 μm spheres,
the adhesion efficiency significantly decreased for all WSR
increases in both channels and was much lower than that of
2 μm spheres due to the high slip velocity and higher dis-
ruptive force associated with large-sized particles [27].
3.5. Size and channel height
Adhesion assays in horizontal chambers with varying channel
height at a fixed WSR of 200 s−1 showed that adhesion of
spherical particles decreased with increases in channel height
from 127 to 762 μm for all particles sizes studied [23]. This
decrease in binding efficiency may be due to a reduction in
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the contribution of the RBC-generated force normally acting at
larger channel heights. The size of the RBC-FL in humans has
been reported to be between 2 and 10 μm depending on the
vessel size, WSR, and blood hematocrit [53,54]. At a fixed
hematocrit, the RBC-FL thickness increases with an increase
in vessel diameter; therefore, there is less RBCs–particle inter-
action near the wall [48,53,54]. Similarly, in a microfluidic
model of human microvessels, adhesion efficiency was higher
in the 28 μm channel relative to the 43 μm channel for all
spheres (0.2–5 μm), although these increases were only sig-
nificant for microspheres [27].
3.6. Size and flow type
The introduction of pulsatility and/or recirculation to flow did not
alter the adhesion trends seen as a function of particle size when
compared to the adhesion trend in laminar flow with equivalent
WSR [23,24]. Particle adhesion increased as particle size increased
from0.5 to 5μm.Nodifference in adhesionwas observedbetween
0.2 and 0.5 μm spheres. sLeA-polystyrene microspheres displayed
significantly higher adhesion levels in both pulsatile flow
(WSR = 1000 s−1 and 1200 s−1) and recirculating flow
(WSR = 200 s−1 and 500 s−1) than their counterparts in laminar
flow at the sameWSRs [24]. The adhesion of nanospheres was not
enhanced with pulsatility in flow [23,24]. An increase in micropar-
ticle adhesion directly correlates with an increase in the residence
time of particles with pulsatile flow relative to laminar flow, sug-
gesting that increased residence time is likely the major factor
contributing to adhesion increase under pulsatile flow [24].
Pauses in flow lead to periods of low slip velocities for large
particles and thus better opportunity for adhesion. The adhesion
of nanosphereswas similar in thepresenceor absenceof pulsatility
in flow, since there are minimal hemodynamic/disruptive forces
acting on nanoparticles compared tomicrospheres, and thus, their
adhesion will be minimally affected by pauses in flow [55].
The binding of polystyrene microspheres in recirculating
reconstituted blood flow in a VSFC (Figure 2(a,b))
(WSR = 200 s−1 and 500 s−1) exhibited an adhesion profile
which peaked in the reattachment area, just beyond the reat-
tachment point (Figure 2(c,d)), due to low parallel shear forces
and a maximum normal velocity on the wall [56], consistent
with previous reports of platelet (∼2 μm) and leukocyte (∼7–15
μm) adhesion in similar VSFC [56,57]. The adhesion of all
spheres in the far downstream region (laminar flow regime
[56]) was significantly higher than in laminar flow in PPFC with
the same height and WSR [24]. Pulsatile flow in the VSFC did
not enhance adhesion when compared with adhesion in lami-
nar flow at the same average WSR in the VSFC, likely because
pulsatile flow disrupts the particle distribution associated with
recirculation flow [24].
In a mouse model of aorta atherosclerotic plaque, the
binding of dual-targeted sLeA/aVCAM-spheres was not
Figure 2. Visualization of flow patterns created in a vertical-step flow channel (VSFC) and typical adhesion profiles of microspheres in VSFC. (a) Schematic diagram of
the flow channel showing the flow pattern immediately beyond the step: h and H are the heights of the channel above the step and beyond the step, respectively.
(b top) Phase-contrast photomicrograph (top view) of experimental flow patterns in the VSFC. Flow is from left to right and is made visible with 1 µm marker
microparticles. Flow separation occurs in the region distal to the step, forming four specific flow areas: a, the stagnant flow area; b, the center of the recirculation
eddy; c, the reattachment flow area; and d, the fully developed flow area. From online microscopic observations, the particles transported from the bulk flow along
the curved streamlines with decreasing velocities toward the wall near the reattachment point (area c). While some of the particles moved forward to rejoin the
mainstream with increasing velocities, others moved in a retrograde direction toward the step as recirculation eddies. These latter particles moved upstream initially
with increasing velocities, and decelerated when approaching the wall of the step (area a), from where they were carried away from the floor of the chamber by
upward curved streamlines. (b bottom) Schematic drawing of the side view of the streamlines in the VSFC deduced from the top-view photograph. (c & d) sLeA-
coated spheres binding in the VSFC with reconstituted blood flow. Far downstream conditions are 200 s−1 and 500 s−1 of laminar WSR, respectively. The dashed
lines represent the observed reattachment points. Reproduced with permission from references [58] and [24].
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significantly altered between different segments except in the
iliac vessels [24], most likely due to their smaller lumen dia-
meters. However, it is difficult to interpret these in vivo data
due to the absence of detailed knowledge of local in vivo
expression patterns, WSRs, and blood flow patterns in the
different vessel segments [24].
Recirculating flow as well as pulsatile flow also enhanced
the adhesion of microrods and did not alter the adhesion
trend seen as a function of particle size [38]. The adhesion of
rods with larger sizes was greater in all areas of the flow,
including the recirculation region, reattachment/stagnation
point, and far downstream area. There was no significant
difference in the binding of short rods, such as 2-μm ESD
rods with ARs of 2 and 4. The adhesion of 500-nm ESD rods
in recirculating and pulsatile flows was minimal, which is
similar to what has been observed in laminar flow [38].
Overall, the above data indicate that microparticles, espe-
cially 2–5 μm spheres and 2-μm ESD rods, are optimal for
targeting the wall in the medium to large vessels relevant in
several CVDs. Spheres with diameters in the 2–5 μm range
display significantly better margination to the wall at inter-
mediate to high WSRs and channel heights than the nan-
ometer-sized spheres. Nanoparticles have much lower
margination efficiency in disturbed human blood flow and
thus may be more challenging for use as drug carriers or
imaging probes in the treatment of atherosclerosis. Results
from pulsatile flow assays may be relevant in diseases affect-
ing the straight segments of medium to large arteries, e.g.
peripheral artery disease and atherosclerosis, while recirculat-
ing flow is relevant around the branching points and curva-
tures in large arteries where atherosclerosis preferentially
develops [34]. The results with laminar flow may be relevant
in the main arterioles (∼100–250 μm diameter) feeding a solid
tumor [59].
4. The importance of shape
Due to the limited availability of techniques to produce
nonspherical biocompatible nanoparticles [60], the majority
of particles used in drug delivery are those with spherical
shape [61]. However, carrier shape has been shown to have
a profound effect on cellular internalization [62–65], circula-
tion half-life [66,67], and margination toward the vessel wall
[21,22], all of which directly affect the targeting ability of
carriers [68]. Compared to spherical particles, nonspherical
particles (Figure 3) appear to have advantages with respect
to circulation and binding efficiency.
4.1. Macrophage uptake and circulation in the blood
Rod-like and disk-like particles are able to circulate in the
blood for longer periods of time than spherical particles [61].
Along with other physicochemical properties such as nano-
particle size, surface charge, and surface functionality, shape
significantly influences particle uptake by macrophages
[62,69] and mammalian cells [67,70,71]. Rod-shaped nano-
and micro-particles of different materials such as polystyrene,
gold, and silica have been found to be endocytosed and
cleared by macrophages of the liver and spleen to a lesser
degree compared to spherical particles [62,64,65]. Similarly,
disk-shaped particles such as elliptical polystyrene disks
remain in the circulation for longer periods of time than
Figure 3. Schematic showing differently-shaped non-spherical particles investigated for vascular wall margination.
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their spherical counterparts [67]. This explains the lower accu-
mulation of rods and disks in the liver and spleen.
Macrophages internalize particles via actin-driven move-
ment of the macrophage membrane, which is independent
of surface chemistry and depends only on the local particle
shape where the cell attaches [62]. Local particle shape, at the
point of cell attachment, has been defined as the angle
between the membrane normal at the point of initial contact
and tangent lines drawn to the particle contour near the point
of initial contact (Figure 4). Local shapes that have low length-
normalized curvature (local particle shape Ω > 45°, where 45°
is the value for spherical particles) inhibit internalization, while
spheres and local shapes that have high length-normalized
curvature (Ω ≤ 45°) permit internalization [62]. Rods or worm-
like particles with very high ARs (large Ω) inhibit or signifi-
cantly reduce phagocytosis, as demonstrated by Champion
et al. [69]. These authors have shown that worm-like polystyr-
ene particles with very high ARs (>20) exhibited negligible
phagocytosis compared to conventional spherical particles of
equal volume. Internalization was possible only at the end
points of the worm-like particles, while attachment anywhere
along the length of the particles inhibited internalization due
to the low curvature [69].
Recently, Liu et al. have also reported that tobacco mosaic
virus (TMV) short rods with ARs of 4 and 8 were internalized
much faster than TMV with the AR of 17 [72]. Huang et al. have
also shown that the clearance rate of mesoporous silica nano-
particles (MSNs) is primarily dependent on the particle shape,
where short-rod MSNs (AR 1.5, length 185 ± 22 nm) have a
more rapid clearance rate than long-rod MSNs (AR 5, length
720 ± 65 nm) [64]. Due to their lower clearance rates, rod-like
and disk-like particles appear to circulate in the blood for
longer than spherical particles, which may contribute to their
higher vascular targeting.
4.2. Vascular wall margination and attachment
Under microvascular blood-free flow conditions at low WSRs
(<250 s−1, physiological shear rates observed in the micro-
circulation), the adhesion of anti-bovine sreum albumin (BSA)
neutrally buoyant polystyrene [73] and non-targeted
mesoporous silicon [40] particles with different shapes
(including spheres, elliptical/circular disks, and rods) to BSA-
and collagen-coated flow chambers, respectively, was inves-
tigated. Rods provide information on the importance of elon-
gation, and circular disks help determine the importance of
flatness, whereas elliptical disks represent a combination of
elongation and flatness. Under disturbed flow conditions, the
adhesion of microparticles of any shape was significantly
greater compared to that under laminar flow [73]. Rod-
shaped particles exhibited significantly higher attachment
compared to spherical particles, and the effect of shape
was amplified by an increase in particle size [40,73].
Another study has also shown that non-neutrally buoyant
silicon elongated microparticles exhibited a higher margina-
tion tendency compared to silica spheres irrespective of size
and density under low WSRs (5–50 s−1) [74] due to their lower
drag and higher contact surface area compared to spheres.
For particles of equal volume even in the nanometer ESD
range, disks adhered about two times more than rods [40].
This can be explained by the slightly larger hydrodynamic
forces exerted over the rods than those on the disks; the larger
surfaces for adhesion exposed by the disks compared to long
rods; and the higher rotational inertia on the rods compared
to the disks. These results show that flatness, elongation, and
adhesion surface area, as well as orientation during particle–
wall interactions, are critical for firm particle adhesion.
However, compared to flatness, elongation and adhesion
area are the dominant factors for adhesion [40,73]. These
data suggest that thin, disk-like particles could more effec-
tively target diseased microvasculature as compared to
spheres and slender rods.
These studies, however, did not examine binding efficiency
between the endothelial cells and the ligands specific for
these cells. In addition, the WSRs investigated in these studies
were those of the microcirculation present in the vasculature
embedded within organ tissues, tumor, or metastasis [75],
which does not represent the circulation in arteries, where
atherosclerosis can exist. Larger WSRs (>100 s−1) are typically
found in the microcirculation of healthy tissue, whereas lower
values are relevant to tumor microcirculation (<100 s−1) [76].
Employing the same concept, iron oxide nanochains have
Figure 4. Local shape illustration and macrophage uptake of elliptical disks. (a) Schematic diagram illustrating how local shape is defined. T? represents the average
of tangential angles near the point of cell contact. Ω is the angle between T? and the membrane normal at the site of attachment, N?. A1, Ω = 2.5° for cell
attachment at end of worm. A2, Ω = 87.5° for cell attachment on side of worm. Reproduced with permission from reference [69]. (b) Time-lapse video microscopy
clips spanning 39 min of macrophages interacting with identical non-opsonized elliptical disk (ED) particles (major axis 14 µm, minor axis 3 µm) from two different
orientations. B1, cell attaches along the major axis of an ED and internalizes it completely in 3 min. B2, cell attaches to the flat side of an identical ED and spreads,
but does not internalize the particle. Continued observation indicated that this particle was not internalized for >110 min. (scale bars: 10 µm). At least three cells
were observed for each orientation of each particle type and size. Similar results were observed in all repetitions. Reproduced with permission from reference [62].
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been developed and constructed from three to four nano-
spheres covalently linked together for microvascular targeting
in the diagnosis and treatment of cancerous and metastasis
diseases [77–83]. However, there have been no reports on the
use of nanochains in atherosclerosis.
Currently, there has been only one report on the effect of
shape on the adhesion of targeted particles to activated
endothelial cells in blood flow in vitro. Thompson et al. investi-
gated the effects of particle shape parameters (volume, AR, and
axis length) on the margination efficacy of targeted sLeA-poly-
styrene spheres and prolate ellipsoids (rods) to an inflamed
endothelial wall from human blood flow in an in vitro model of
human vasculature, PPFC system, using reconstituted bloodwith
laminar flow and disturbed flows, including pulsatile and recir-
culating flows, at a range of physiological WSRs (120–1200 s−1)
[38]. Rod-shaped microparticles (1or 2 μm ESD) with high ARs (9
and 11) displayed significantly improved margination compared
to spheres of equal volume, particularly under high WSRs and
disturbed flow profiles. The higher the AR or the longer the
major axis, the better the adhesion of the rods, especially at
high WSR (500–1000 s−1) [84,85]. In disturbed flows such as
pulsatile and recirculating flows, similar trends of adhesion
were seen as in steady laminar flow. Nanorods (500 nm ESD),
even with a high AR such as 10, do not display enhanced
margination compared to equivalent spheres. It has been
shown that a minimum major axis length for rods, rather than
a minimum AR, is required for enhanced transportation to the
wall, much like it has been shown that a minimum particle
diameter (∼2 μm) is required for the effective margination of
spheres [86]. In this study, it was shown that the minimummajor
axis length is 5.9 μm [38]. Using modeling, Decuzzi et al. also
predicted that the lateral drift velocity of discoidal microparticles
increases (i.e. they undergo faster collisions with the wall) with
increased particle elongation/major axis [87]. Due to limitations
in current rod-fabrication techniques [88], it was not possible to
fabricate rods of 500 nm ESD with a major axis greater than 2.5
μm, thus limiting the capacity to test this hypothesis for nanor-
ods [38].
In a mouse model of atherosclerosis, dual-targeted poly-
styrene microrods (2 μm ESD) also displayed significantly
higher adhesion densities than polystyrene microspheres (2
μm), while nanorods displayed no increased adhesion com-
pared to equivalent 500-nm diameter spheres [15]. Among
targeted rods of three different ARs (2, 4, and 9) with 2 μm
ESD, the adhesion of the AR4 rods was the highest (∼3 times
higher) relative to the equivalent microspheres [15]. The adhe-
sion of the AR2 and AR9 rods was roughly the same as for 2
μm spheres and lower than that of the AR4 rods. This differs
from what has been observed in vitro where AR9 rods exhib-
ited higher adhesion compared to AR2 and AR4 rods [38]. This
is likely because of the relatively small difference in local shape
and surface area between AR2 rods and spheres. The lower
adhesion of AR9 rods compared to AR4 rods, despite their
higher contact surface area, is likely due to their entrapment in
the capillaries as AR9 rods have a major axis length of roughly
9 μm [15]. Recently, Wen et al. have also demonstrated that
rod-shaped particles (elongated TMV) functionalized with
binding peptides and contrast agents (gadolinium) could be
targeted to activated platelets/thrombus in mouse carotid
artery at a higher magnitude compared to sphere-like particles
(icosahedral cowpea mosaic virus) [89].
Overall, nonspherical particles are more appropriate than
spherical beads as carriers for targeting to the vascular walls
under flow. Oblong particles exhibited higher adhesion magni-
tudes than their spherical counterparts. This can be explained
by the longer circulation of oblongs in the blood compared to
spheres. In addition, elongated particles are subjected to torque
forces within blood flow, and therefore, they have a tendency
to tumble out of the general circulation and scavenge along
vessel walls [40,73,77,87] (Figure 5(a)). Spherical particles, on the
other hand, tend to follow the streamlines. Furthermore, experi-
mental and computational modeling data show that spherical
microparticles experience the largest dislodging forces and
exhibit the smallest areas of adhesion, followed by rods and
then disks. Particle elongation and flatness increase the particle
surface area in contact with the endothelium and thereby
present a greater number of targeting ligands to the endothe-
lium in cases where all particles have a fixed ligand density, as
illustrated in Figure 5(b). This is because their ligands are
arranged on a planar surface and available in greater numbers,
in comparison to spherical particles where curvature limits the
number of ligands available for binding in a given instance
[90,91]. The higher contact area with the endothelium exhibited
by rods and disks distributes their adhesive force over a larger
surface area, and therefore a higher shear force required to
remove an adherent particle from the vascular surface.
The streamlined shape of rods and disks also reduces the
removal force due to the blood flow felt by these particles at
the endothelium compared to an equivalent sphere [35]. The
drag force exerted over a rod or disk is orientation dependent,
and it reaches a maximum for a rod/disk lying with its major
axis orthogonal to the flow. Disks and rods aligned with the
flow experience the lowest drag force. For the hydrodynamic
torque T, small variations were observed among the different
particles [40]. Oblong particles aligned with the flow direction
or immersed in a shear flow near a wall rotated more slowly
compared to spherical particles [92]. In addition, the effect of
the wall leads to several viscous interactions that do not exist
for spherical particles. Therefore, nonspherical particles are
able to adhere more strongly to the vascular wall.
However, these interactions disappear for oblong particles
with very small ARs [92]. The lack of improved adhesion of
nanorods compared to nanospheres is likely due to the general
inability of nanoparticles to preferentially segregate to the
RBC-FL and the diminished impact of a higher contact surface
area on adhesion for these particles. However, nanodisks in
low shear buffer flows exhibit around twofold greater adhe-
sion over rods of equal volume, most likely due to slightly
higher hydrodynamic forces exerted on the rods compared
to disks and the larger surfaces for adhesion exposed by
disks relative to rods [40]. However, the differences in binding
of rods and disks to endothelial cells have not, however, been
investigated in blood flow.
5. The effect of particle density
A wide range of materials with different densities is used for
drug delivery and diagnostics. Gas-filled microbubbles [93–96]
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have densities roughly 1% that of blood [97]. Common bio-
compatible and the FDA-approved polymeric particles
[13,91,98,99], such as poly(lactic acid), poly(glycolic acid),
poly(methyl methacrylate), polycaprolactone, and poly (lactic-
co-glycolic acid), and protein-based nanoparticles tend to
have densities either neutrally buoyant or slightly higher
than that of blood [100,101]. Liposomes [102,103] are often
neutrally buoyant but can have varied densities depending on
the density of the medium encapsulated within the liposome
[104,105]. Inorganic particles (e.g. silica, titanium, gold, and
iron oxide) [106–109] usually have densities much higher
than that of blood (silica oxide: 2.0 g ml−1, titanium: 3.9 g
ml−1, iron oxide: 5.24 g ml−1, and gold: 19.3 g ml−1). Despite
the wide range of densities of vascular-targeting materials,
there have been limited investigations of the effect of particle
density on vascular margination and adhesion. Particle density
forces are usually regarded as negligible in describing particle
motion relevant to physiological blood flow [25], since the
hydrodynamic forces due to flow (for microparticles) and
Brownian forces (for nanoparticles) are often orders of magni-
tude higher than density-dependent body forces such as grav-
itational and centrifugal forces [87].
Recently, Thompson et al. have reported the effect of
material density on the margination and adhesion efficiency
of particles to the vascular wall [25]. The targeting of 500-nm
sLeA-coated polystyrene, silica, and titanium nanospheres
(densities of 1.05, 2.0, and 3.9 g ml−1, respectively) to inflamed
endothelium from human blood flow in a PPFC, an in vitro
model of human vasculature, was investigated. Silica spheres,
which have a density roughly twice that of blood, exhibited
improved adhesion to inflamed endothelium compared to
neutrally buoyant polystyrene spheres of the same size, in
both horizontal and inverted chambers. An RBC effect was
observed with silica spheres as they displayed better near-
wall localization in the presence of RBCs than in pure buffer,
likely resulting in the observed improvement in adhesion.
Titanium spheres, which have a density around four times
higher than that of blood, adhered at levels higher than poly-
styrene, but only in conditions where gravity or centrifugal
force acted in the direction of adhesion [25]. Similar to what
has been observed with polystyrene microspheres [23], both
silica and titanium particles exhibited reduced adhesion effi-
ciency as the WSR increased from 100 s−1 to 1000 s−1 [25]. In a
VSFC, adhesion within the recirculation region increased for
silica and titanium particles compared to polystyrene in both
upright and inverted chambers. In the far downstream region,
the adhesion for silica and titanium spheres was also higher
than for polystyrene spheres when the chamber was upright,
while there was no significant difference between particle
types far downstream in the inverted chamber. However, the
Figure 5. Effects of the morphology of the particles on their margination and binding strength (avidity). (a) Margination: Non-spherical particles such as disks and
rods are subjected to torque forces within blood flow, and therefore they have a tendency to tumble out of the general circulation and scavenge along vessel walls.
Spherical particles, on the other hand, tend to follow the streamlines. (b) Binding avidity: Particle elongation and flatness increase the particle surface area in contact
with the endothelium and thereby present a greater number of targeting ligands to the endothelium in cases where all particles have a fixed ligand density,
resulting in stronger binding strength.
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improved adhesion of dense nanoparticles in recirculation
flow diminished in an inverted channel. This may be because
the negative gravity component overrides any benefit of the
recirculation flow. The adhesion of silica and titanium in the
recirculating flow pattern and further downstream was not
significantly different, suggesting that the two particles were
distributed to the wall area about the same amount [25].
These findings are in contrast to those of a previous study
which has shown that increased density had a negative effect
on the margination of nanospheres with diameters ranging
from 60 to 65 nm [104]. This can be explained because the
gravity component for the 65 nm spheres is negligible and the
decreased margination is attributable to the increased particle
momentum competing with Brownian motion toward the
chamber wall. However, this study was conducted with buffer
flow, not blood flow.
6. Conclusions
The physical characteristics of particles should be considered in
the design of carrier systems to target atherosclerosis, as these
parameters significantly affect carrier performance. Current stu-
dies show that particle size, shape, and density, along with local
hemodynamic conditions including shear rate, flow type, chan-
nel height, and the presence of RBCs, all determine how well
targeted carrier systems adhere to the activated endothelial cell
layers or vascular walls at the sites of atherosclerosis. Regardless
of shape, microparticles display better adhesion than nanopar-
ticles. Pulsatility and recirculation in blood flow further enhance
the margination of microspheres while having minimal effect
on the adhesion of nanospheres. Nonspherical particles are less
taken up or less cleared by macrophages and exhibit higher
adhesion than their spherical counterparts. Disks perform better
than rods of equivalent volume. However, no studies on the
adhesion of disks to endothelial cells in vitro or in vivo have
been reported. The increased density of the targeted particles
also has a positive effect on the margination. These findings
provide general design principles that can serve as guidelines
to develop carriers for the delivery of therapeutic and imaging
agents in CVD and beyond.
7. Expert opinion
Despite significant clinical advancements in the field, CVDs such
as atherosclerosis remain the leading cause of death and dis-
ability worldwide. Targeting of nanomedicine to atherosclerosis
can be achieved via the main lumen or the vasa vasorum at
lesioned site; however, studies on the vasa vasorum in athero-
sclerosis targeting are limited. Although current evidence shows
that nonspherical microparticles exhibit higher margination and
adhesion to vascular walls under shear rates, it cannot be con-
cluded that these particles are optimal for drug delivery in CVD.
While particles with diameters on the micrometer scale have
been shown to adhere more efficiently to the endothelial cell
surface, they are potentially susceptible to physical entrapment
in the capillaries in vivo. In addition, there is a lack of thorough
understanding of the side effects, degradation, and toxicity of
nonspherical particles at different biological levels such as the
body, organs, and cells.
Nanoparticles such as nanospheres, on the other hand, have
characteristics that make them attractive for use in drug deliv-
ery, including their ease of synthesis and fabrication and their
capacity to undergo endocytosis and transcytosis upon contact
with the endothelium. However, they are unable to efficiently
marginate to the vascular wall, limiting their efficacy as a vas-
cular-targeted carrier system for diseases affecting medium to
large blood vessels such as atherosclerosis. Nevertheless, pre-
liminary studies are encouraging for further exploration of the
use of nano-constructs, as delivery systems for vascular target-
ing in CVD, characterized by a sub-micrometer size and a den-
sity higher than that of blood in order to maximize their near-
wall accumulation within the RBC-FL while avoiding entrapment
in the lungs and small capillaries and a nonspherical shape to
enhance their lateral drift toward the vessel walls and their
ligand–receptor interaction with the vessel walls.
Generally, the effects of particle size, shape, and density
should be considered simultaneously in designing vascular-
targeting carriers for CVD. Although disk-like particles exhibit
higher adhesion magnitude than rod-like particles of the same
volume, there has been no investigation of differences in
binding in blood flow in vitro and in vivo. An important con-
sideration associated with the use of dense materials for drug
carriers in atherosclerosis is whether the high-velocity colli-
sions of high-density particles (e.g. gold nanoparticles) with
the vascular wall could potentially cause adverse effects on
the endothelium itself. This is especially critical in late-stage
atherosclerosis, when a significant disruption in the endothe-
lium could potentially lead to clot formation. There is a lack of
study on the role of particle’s rigidity or deformable particles
on vascular margination and targeting. This aspect should be
investigated using nanoparticles of different rigidity but with
the same chemical composition, size, and surface properties.
In addition, there is a clear need for thorough studies of the
cellular uptake of particles of different size, shape, and density
under different flow conditions, particularly those relevant to
atherosclerosis. Other shapes as well as other strategies need
to be explored for improving the margination performance of
nanoparticles in human blood flow, especially for application
in medium to large blood vessels, which are the most relevant
in CVD. Due to synthetic difficulty, spherical nanoparticles still
dominate in tests and trials. Therefore, further work is needed
to develop synthetic strategies to produce particles in differ-
ent shapes with tunable sizes, while maintaining narrow size
distributions and homogeneity. Last but not least, the effect of
particle’s physical properties on plaque targeting from the
vasa vasorum site should be thoroughly investigated.
Funding
This work is funded by National Health and Medical Research Council
[AP1037310, FT0992210], and the Australian Research Council
[CE140100036].
Declaration of interest
The authors were supported by National Health and Medical Research
Council and the Australian Research Council. The authors have no other
relevant affiliations or financial involvement with any organization or
10 H. T. TA ET AL.
entity with a financial interest in or financial conflict with the subject
matter or materials discussed in the manuscript apart from those
disclosed.
References
Papers of special note have been highlighted as either of interest (•) or of
considerable interest (••) to readers.
1. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke
statistics – 2015 update. Circulation. 2015;131:e30–e320.
2. Hajitou A, Pasqualini R, Arap W. Vascular targeting: recent advances
and therapeutic perspectives. Trends Cardiovasc Med. 2006;16:80–88.
3. Psarros C, Lee R, Margaritis M, et al. Nanomedicine for the preven-
tion, treatment and imaging of atherosclerosis. Nanomedicine.
2012;8(Suppl 1):S59–68.
4. Hansson GK. Inflammation, atherosclerosis, and coronary artery
disease. N Engl J Med. 2005;352:1685–1695.
5. Gawaz M, Langer H, May AE. Platelets in inflammation and ather-
ogenesis. J Clin Invest. 2005;115:3378–3384.
6. Falk E. Pathogenesis of atherosclerosis. J Am Coll Cardiol. 2006;47:
C7–12.
• This is a comprehensive review on pathogenesis of
atherosclerosis.
7. Virmani R, Kolodgie FD, Burke AP, et al. Lessons from sudden
coronary death: a comprehensive morphological classification
scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol.
2000;20:1262–1275.
8. Lobatto ME, Fuster V, Fayad ZA, et al. Perspectives and opportu-
nities for nanomedicine in the management of atherosclerosis. Nat
Rev Drug Discov. 2011;10:835–852.
9. Chung BL, Toth MJ, Kamaly N, et al. Nanomedicines for endothelial
disorders. Nano Today. 2015;10:759–776.
10. Bicknell R. Vascular targeting and the inhibition of angiogenesis.
Ann Oncol. 1994;5(Suppl 4):45–50.
11. Schnitzer JE. Vascular targeting as a strategy for cancer therapy. N
Engl J Med. 1998;339:472–474.
12. Bendas G, Krause A, Schmidt R, et al. Selectins as new targets for
immunoliposome-mediated drug delivery. A potential way of anti-
inflammatory therapy. Pharm Acta Helv. 1998;73:19–26.
13. Muro S, Dziubla T, Qiu W, et al. Endothelial targeting of high-
affinity multivalent polymer nanocarriers directed to intercellular
adhesion molecule 1. J Pharmacol Exp Ther. 2006;317:1161–1169.
14. Sakhalkar HS, Dalal MK, Salem AK, et al. Leukocyte-inspired biode-
gradable particles that selectively and avidly adhere to inflamed
endothelium in vitro and in vivo. Proc Natl Acad Sci U S A.
2003;100:15895–15900.
15. NamdeeK, ThompsonAJ, Golinski A, et al. In vivo evaluation of vascular-
targeted spheroidal microparticles for imaging and drug delivery appli-
cation in atherosclerosis. Atherosclerosis. 2014;237:279–286.
•• An interesting article showing effect of particle size and shape
on vascular targeting in vivo using a mouse model of
atherosclerosis.
16. Anderson SA, Rader RK, Westlin WF, et al. Magnetic resonance
contrast enhancement of neovasculature with alpha(v)beta(3)-tar-
geted nanoparticles. Magn Reson Med. 2000;44:433–439.
17. Kiani MF, Yuan H, Chen X, et al. Targeting microparticles to select
tissue via radiation-induced upregulation of endothelial cell adhe-
sion molecules. Pharm Res. 2002;19:1317–1322.
18. Moghimi SM, Porter CJ, Muir IS, et al. Non-phagocytic uptake of
intravenously injected microspheres in rat spleen: influence of
particle size and hydrophilic coating. Biochem Biophys Res
Commun. 1991;177:861–866.
19. Abra RM, Hunt CA. Liposome disposition in vivo. III. Dose and
vesicle-size effects. Biochim Biophys Acta. 1981;666:493–503.
20. Decuzzi P, Ferrari M. The adhesive strength of non-spherical particles
mediated by specific interactions. Biomaterials. 2006;27:5307–5314.
21. Decuzzi P, Pasqualini R, Arap W, et al. Intravascular delivery of
particulate systems: does geometry really matter?. Pharm Res.
2009;26:235–243.
22. Park JH, vonMaltzahnG, Zhang L, et al. Magnetic iron oxide nanoworms
for tumor targeting and imaging. Adv Mater. 2008;20:1630–1635.
23. Charoenphol P, Huang RB, Eniola-Adefeso O. Potential role of size
and hemodynamics in the efficacy of vascular-targeted spherical
drug carriers. Biomaterials. 2010;31:1392–1402.
•• An excellent study showing effect of particle’s size, hematocrit,
channel orientation, channel height, wall shear rate, and flow
type on vascular targeting.
24. Charoenphol P, Mocherla S, Bouis D, et al. Targeting therapeutics
to the vascular wall in atherosclerosis – carrier size matters.
Atherosclerosis. 2011;217:364–370.
• An excellent article showing effect of particle size on vascular
targeting in vitro.
25. Thompson AJ, Eniola-Adefeso O. Dense nanoparticles exhibit
enhanced vascular wall targeting over neutrally buoyant nanopar-
ticles in human blood flow. Acta Biomater. 2015;21:99–108.
•• An article showing the effect of particle density on vascular
targeting.
26. Lee TR, Choi M, Kopacz AM, et al. On the near-wall accumulation of
injectable particles in the microcirculation: smaller is not better. Sci
Rep. 2013;3:2079.
27. Namdee K, Thompson AJ, Charoenphol P, et al. Margination propen-
sity of vascular-targeted spheres from blood flow in a microfluidic
model of human microvessels. Langmuir. 2013;29:2530–2535.
28. Migliorini C, Qian Y, Chen H, et al. Red blood cells augment leukocyte
rolling in a virtual blood vessel. Biophys J. 2002;83:1834–1841.
29. Munn LL, Melder RJ, Jain RK. Role of erythrocytes in leukocyte-
endothelial interactions: mathematical model and experimental
validation. Biophys J. 1996;71:466–478.
30. Hammer DA. Leukocyte adhesion: what’s the catch?. Curr Biol.
2005;15:R96–9.
31. Sun C, Migliorini C, Munn LL. Red blood cells initiate leukocyte
rolling in postcapillary expansions: a lattice Boltzmann analysis.
Biophys J. 2003;85:208–222.
32. Nobis U, Pries AR, Cokelet GR, et al. Radial distribution of white cells
during blood flow in small tubes. Microvasc Res. 1985;29:295–304.
33. Guyton AC, Hall JE. Textbook of medical physiology. 11th ed.
Philadelphia: Elsevier, Inc.; 2006.
34. Chiu JJ, Chien S. Effects of disturbed flow on vascular endothelium:
pathophysiological basis and clinical perspectives. Physiol Rev.
2011;91:327–387.
•• An interesting review on blood flow in pathophysiological
conditions.
35. Atukorale PU, Covarrubias G, Bauer L, et al. Vascular targeting of
nanoparticles for molecular imaging of diseased endothelium. Adv
Drug Deliv Rev. 2016. doi: 10.1016/j.addr.2016.09.006
36. Stone PH, Saito S, Takahashi S, et al. Prediction of progression of
coronary artery disease and clinical outcomes using vascular profil-
ing of endothelial shear stress and arterial plaque characteristics:
the PREDICTION Study. Circulation. 2012;126:172–181.
•• An excellent study on blood flow and its effect on progression
of coronary artery disease.
37. Ku DN, Giddens DP, Zarins CK, et al. Pulsatile flow and atherosclero-
sis in the human carotid bifurcation. Positive correlation between
plaque location and low oscillating shear stress. Arteriosclerosis.
1985;5:293–302.
38. Thompson AJ, Mastria EM, Eniola-Adefeso O. The margination pro-
pensity of ellipsoidal micro/nanoparticles to the endothelium in
human blood flow. Biomaterials. 2013;34:5863–5871.
39. Huang RB, Mocherla S, Heslinga MJ, et al. Dynamic and cellular
interactions of nanoparticles in vascular-targeted drug delivery.
Mol Membr Biol. 2010;27:312–327.
40. Adriani G, De Tullio MD, Ferrari M, et al. The preferential targeting
of the diseased microvasculature by disk-like particles. Biomaterials.
2012;33:5504–5513.
• An article showing better adhesion of disk-like particles com-
pared to rods.
41. Charoenphol P, Onyskiw PJ, Carrasco-Teja M, et al. Particle-cell
dynamics in human blood flow: implications for vascular-targeted
drug delivery. J Biomech. 2012;45:2822–2828.
EXPERT OPINION ON DRUG DELIVERY 11
42. Sharan M, Popel AS. A two-phase model for flow of blood in
narrow tubes with increased effective viscosity near the wall.
Biorheology. 2001;38:415–428.
43. Koutsiaris AG, Tachmitzi SV, Batis N, et al. Volume flow and wall
shear stress quantification in the human conjunctival capillaries
and post-capillary venules in vivo. Biorheology. 2007;44:375–386.
44. Nagaoka T, Yoshida A. Noninvasive evaluation of wall shear stress
on retinal microcirculation in humans. Invest Ophthalmol Vis Sci.
2006;47:1113–1119.
45. Tilles AW, Eckstein EC. The near-wall excess of platelet-sized parti-
cles in blood flow: its dependence on hematocrit and wall shear
rate. Microvasc Res. 1987;33:211–223.
46. Eckstein EC, Tilles AW, Millero FJ. Conditions for the occurrence of
large near-wall excesses of small particles during blood flow.
Microvasc Res. 1988;1:31–39.
47. Abbitt KB, Nash GB. Characteristics of leucocyte adhesion directly
observed in flowing whole blood in vitro. Br J Haematol.
2001;112:55–63.
48. Kim S, Kong RL, Popel AS, et al. Temporal and spatial variations of
cell-free layer width in arterioles. Am J Physiol Heart Circ Physiol.
2007;293:H1526–35.
49. Pappu V, Bagchi P. Hydrodynamic interaction between erythro-
cytes and leukocytes affects rheology of blood in microvessels.
Biorheology. 2007;44:191–215.
50. Shinde Patil VR, Campbell CJ, Yun YH, et al. Particle diameter
influences adhesion under flow. Biophys J. 2001;80:1733–1743.
51. Chang KC, Hammer DA. The forward rate of binding of surface-
tethered reactants: effect of relative motion between two surfaces.
Biophys J. 1999;76:1280–1292.
52. Slack SM, Turitto VT. Fluid dynamic and hemorheologic considera-
tions. Cardiovasc Pathol. 1993;2:11S–21S.
53. Kim S, Ong PK, Yalcin O, et al. The cell-free layer in microvascular
blood flow. Biorheology. 2009;46:181–189.
54. Maeda N, Suzuki Y, Tanaka J, et al. Erythrocyte flow and elasticity of
microvessels evaluated by marginal cell-free layer and flow resis-
tance. Am J Physiol. 1996;271:H2454–61.
55. Decuzzi P, Ferrari M. Design maps for nanoparticles targeting the
diseased microvasculature. Biomaterials. 2008;29:377–384.
56. Skilbeck C, Westwood SM, Walker PG, et al. Dependence of adhe-
sive behavior of neutrophils on local fluid dynamics in a region
with recirculating flow. Biorheology. 2001;38:213–227.
57. Skilbeck CA, Walker PG, David T, et al. Disturbed flow promotes
deposition of leucocytes from flowing whole blood in a model of a
damaged vessel wall. Br J Haematol. 2004;126:418–427.
58. Chiu JJ, Chen CN, Lee PL, et al. Analysis of the effect of disturbed
flow on monocytic adhesion to endothelial cells. J Biomech.
2003;36:1883–1895.
59. Less JR, Skalak TC, Sevick EM, et al. Microvascular architecture in a
mammary carcinoma: branching patterns and vessel dimensions.
Cancer Res. 1991;51:265–273.
60. Champion JA, Karate YK, Samir M. Particle shape: a new design
parameter for micro- and nanoscale drug delivery carriers. J Control
Release. 2007;121:1–2.
61. Truong NP, Whittaker MR, Mak CW, et al. The importance of nano-
particle shape in cancer drug delivery. Expert Opin Drug Deliv.
2015;12:129–142.
62. Champion JA, Mitragotri S. Role of target geometry in phagocyto-
sis. Proc Natl Acad Sci U S A. 2006;103:4930–4934.
63. Gratton SE, Ropp PA, Pohlhaus PD, et al. The effect of particle
design on cellular internalization pathways. Proc Natl Acad Sci U
S A. 2008;105:11613–11618.
64. Huang X, Li L, Liu T, et al. The shape effect of mesoporous silica
nanoparticles on biodistribution, clearance, and biocompatibility in
vivo. ACS Nano. 2011;5:5390–5399.
65. Arnida, Janat-Amsbury MM, Ray A, et al. Geometry and surface char-
acteristics of gold nanoparticles influence their biodistribution and
uptake by macrophages. Eur J Pharm Biopharm. 2011;77:417–423.
66. Geng Y, Dalhaimer P, Cai S, et al. Shape effects of filaments versus
spherical particles in flow and drug delivery. Nat Nanotechnol.
2007;2:249–255.
67. Muro S, Garnacho C, Champion JA, et al. Control of endothelial
targeting and intracellular delivery of therapeutic enzymes by
modulating the size and shape of ICAM-1-targeted carriers. Mol
Ther. 2008;16:1450–1458.
• An interesting article on prolonged circulation and cellular
uptake of elliptical disks.
68. Truong NP, Quinn JF, Whittaker MR, et al. Polymeric filomicelles
and nanoworms: two decades of synthesis and application. Polym
Chem. 2016;7:4295–4312.
69. Champion JA, Mitragotri S. Shape induced inhibition of phagocy-
tosis of polymer particles. Pharm Res. 2009;26:244–249.
•• An interesting article on cellular uptake of rod- or worm-like
particles.
70. Huang X, Teng X, Chen D, et al. The effect of the shape of meso-
porous silica nanoparticles on cellular uptake and cell function.
Biomaterials. 2010;31:438–448.
71. Chithrani BD, Ghazani AA, Chan WC. Determining the size and
shape dependence of gold nanoparticle uptake into mammalian
cells. Nano Lett. 2006;6:662–668.
72. Liu X, Wu F, Tian Y, et al. Size dependent cellular uptake of rod-like
bionanoparticles with different aspect ratios. Sci Rep. 2016;6:24567.
73. Doshi N, Prabhakarpandian B, Rea-Ramsey A, et al. Flow and adhe-
sion of drug carriers in blood vessels depend on their shape: a
study using model synthetic microvascular networks. J Control
Release. 2010;146:196–200.
• An article showing that rod-shaped particles exhibited signifi-
cantly higher vascular attachment compared to spherical particles.
74. Gentile F, Chiappini C, Fine D, et al. The effect of shape on the
margination dynamics of non-neutrally buoyant particles in two-
dimensional shear flows. J Biomech. 2008;41:2312–2318.
75. Liang S, Slattery MJ, Wagner D, et al. Hydrodynamic shear rate
regulates melanoma-leukocyte aggregation, melanoma adhesion
to the endothelium, and subsequent extravasation. Ann Biomed
Eng. 2008;36:661–671.
76. Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors.
Nat Rev Clin Oncol. 2010;7:653–664.
77. Peiris PM, Toy R, Doolittle E, et al. Imaging metastasis using an
integrin-targeting chain-shaped nanoparticle. ACS Nano.
2012;6:8783–8795.
78. Peiris PM, Schmidt E, Calabrese M, et al. Assembly of linear nano-
chains from iron oxide nanospheres with asymmetric surface
chemistry. Plos One. 2011;6:e15927.
79. Peiris PM, Bauer L, Toy R, et al. Enhanced delivery of chemotherapy
to tumors using a multicomponent nanochain with radio-fre-
quency-tunable drug release. ACS Nano. 2012;6:4157–4168.
80. Peiris PM, Tam M, Vicente P, et al. On-command drug release from
nanochains inhibits growth of breast tumors. Pharm Res.
2014;31:1460–1468.
81. Peiris PM, Toy R, Abramowski A, et al. Treatment of cancer micro-
metastasis using a multicomponent chain-like nanoparticle. J
Control Release. 2014;173:51–58.
82. Peiris PM, Abramowski A, McGinnity J, et al. Treatment of invasive
brain tumors using a chain-like nanoparticle. Cancer Res.
2015;75:1356–1365.
83. Peiris PM, Deb P, Doolittle E, et al. Vascular targeting of a gold nano-
particle to breast cancermetastasis. J Pharm Sci. 2015;104:2600–2610.
84. Simone E, Ding BS, Muzykantov V. Targeted delivery of therapeu-
tics to endothelium. Cell Tissue Res. 2009;335:283–300.
85. Champion JA, Katare YK, Mitragotri S. Making polymeric micro- and
nanoparticles of complex shapes. Proc Natl Acad Sci U S A.
2007;104:11901–11904.
86. Backer MV, Gaynutdinov TI, Patel V, et al. Vascular endothelial
growth factor selectively targets boronated dendrimers to tumor
vasculature. Mol Cancer Ther. 2005;4:1423–1429.
87. Lee SY, Ferrari M, Decuzzi P. Shaping nano-/micro-particles for
enhanced vascular interaction in laminar flows. Nanotechnology.
2009;20:495101.
88. Truong NP, Whittaker MR, Anastasaki A, et al. Facile production of
nanoaggregates with tuneable morphologies from thermorespon-
sive P(DEGMA-co-HPMA). Polym Chem. 2016;7:430–440.
12 H. T. TA ET AL.
89. Wen AM, Wang Y, Jiang K, et al. Shaping bio-inspired nanotechnol-
ogies to target thrombosis for dual optical-magnetic resonance
imaging. J Mater Chem B Mater Biol Med. 2015;3:6037–6045.
90. Kolhar P, Anselmo AC, Gupta V, et al. Using shape effects to target
antibody-coated nanoparticles to lung and brain endothelium.
Proc Natl Acad Sci U S A. 2013;110:10753–10758.
91. Shuvaev VV, Ilies MA, Simone E, et al. Endothelial targeting of anti-
body-decorated polymeric filomicelles. ACS Nano. 2011;5:6991–6999.
92. Gavze E, Shapiro M. Motion of inertial spheroidal particles in a
shear flow near a solid wall with special application to aerosol
transport in microgravity. J Fluid Mech. 1998;371:59–79.
• A study using modeling to investigate the effect of particle’s
shape on vascular targeting.
93. Unger E, Porter T, Lindner J, et al. Cardiovascular drug delivery with
ultrasound and microbubbles. Adv Drug Deliv Rev. 2014;72:110–126.
94. Ting CY, Fan CH, Liu HL, et al. Concurrent blood-brain barrier
opening and local drug delivery using drug-carrying microbubbles
and focused ultrasound for brain glioma treatment. Biomaterials.
2012;33:704–712.
95. Wang X, Gkanatsas Y, Palasubramaniam J, et al. Thrombus-targeted
theranostic microbubbles: a new technology towards concurrent
rapid ultrasound diagnosis and bleeding-free fibrinolytic treatment
of thrombosis. Theranostics. 2016;6:726–738.
96. Wang X, Hagemeyer CE, Hohmann JD, et al. Novel single-chain
antibody-targeted microbubbles for molecular ultrasound imaging
of thrombosis: validation of a unique noninvasive method for rapid
and sensitive detection of thrombi and monitoring of success or
failure of thrombolysis in mice. Circulation. 2012;125:3117–3126.
97. Takalkar AM, Klibanov AL, Rychak JJ, et al. Binding and detachment
dynamics of microbubbles targeted to P-selectin under controlled
shear flow. J Control Release. 2004;96:473–482.
98. Nance E, Zhang C, Shih TY, et al. Brain-penetrating nanoparticles
improve paclitaxel efficacy in malignant glioma following local
administration. ACS Nano. 2014;8:10655–10664.
99. Kamaly N, Xiao Z, Valencia PM, et al. Targeted polymeric therapeu-
tic nanoparticles: design, development and clinical translation.
Chem Soc Rev. 2012;41:2971–3010.
100. Koo OM, Rubinstein I, Onyuksel H. Role of nanotechnology in
targeted drug delivery and imaging: a concise review.
Nanomedicine. 2005;1:193–212.
101. Kim W, Haller C, Dai E, et al. Targeted antithrombotic protein
micelles. Angew Chem Int Ed Engl. 2015;54:1461–1465.
102. Allen TM. Long-circulating (sterically stabilized) liposomes for tar-
geted drug delivery. Trends Pharmacol Sci. 1994;15:215–220.
103. Allen TM, Cullis PR. Liposomal drug delivery systems: from concept
to clinical applications. Adv Drug Deliv Rev. 2013;65:36–48.
104. Toy R, Hayden E, Shoup C, et al. The effects of particle size, density
and shape on margination of nanoparticles in microcirculation.
Nanotechnology. 2011;22:115101.
105. Singh AK, Cummings EB, Throckmorton DJ. Fluorescent liposome
flow markers for microscale particle-image velocimetry. Anal Chem.
2001;73:1057–1061.
106. Liong M, Lu J, Kovochich M, et al. Multifunctional inorganic nano-
particles for imaging, targeting, and drug delivery. ACS Nano.
2008;2:889–896.
107. Huang HC, Barua S, Sharma G, et al. Inorganic nanoparticles for
cancer imaging and therapy. J Control Release. 2011;155:344–357.
108. Tom RT, Suryanarayanan V, Reddy PG, et al. Ciprofloxacin-protected
gold nanoparticles. Langmuir. 2004;20:1909–1914.
109. Ta HT, Prabhu S, Leitner E, et al. Enzymatic single-chain antibody
tagging: a universal approach to targeted molecular imaging and
cell homing in cardiovascular disease. Circ Res. 2011;109:365–373.
EXPERT OPINION ON DRUG DELIVERY 13
